Ye et al. [37] utilized the CK2 inhibitor CX4945 to inhibit Th1 and Th17 cell responses while promoting Th2 cell responses in RA, which significantly dampened IFN-γ and IL-17A production and alleviated the inflammatory state. This evidence concerns the gene IL17A and rheumatoid arthritis.